장마감
로그인 회원가입
QGEN
QGEN
Qiagen NV
7월 27일 4:00 PM ET (한국 7/28 05:00)
$41.08
-0.29 ▼ -0.70%
🌙 7월 27일 5:05 PM ET (한국 7/28 06:05)
$40.80
-0.28 ▼ -0.68%

키아젠(QGEN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$8.5B
스몰캡
P/E
21.2
적정 수준
배당수익률
0.65%
52주 위치
34%
저점 +26% · 고점 -29%
애널리스트
매수
C+
Fundamental health
vs. Diagnostics & Research
수익성 ⓘ
Top 18%
성장 ⓘ
Top 64%
밸류에이션 ⓘ
Top 81%
재무 안정 ⓘ
Top 41%
Index ⓘ -P/E ⓘ 21.22EPS (ttm) ⓘ 1.94Insider Own ⓘ 0.6%Shs Outstand ⓘ 206.3MPerf Week ⓘ 1.48%
Market Cap ⓘ 8.47BForward P/E ⓘ 15.82EPS next Y ⓘ 7.87%Insider Trans ⓘ -Shs Float ⓘ 204.8MPerf Month ⓘ 5.5%
Enterprise Value ⓘ 9.47BPEG ⓘ 2.67EPS next Q ⓘ 0.6Inst Own ⓘ 79.9%Short Float ⓘ 3.87%Perf Quarter ⓘ 6.95%
Income ⓘ 0.40BP/S ⓘ 4.03EPS this Y ⓘ 1.16%Inst Trans ⓘ 15.47%Short Ratio ⓘ 2.92Perf Half Y ⓘ -26.14%
Sales ⓘ 2.10BP/B ⓘ 2.54EPS next 5Y ⓘ 5.93%ROA ⓘ 7.1%Short Interest ⓘ 7.93MPerf YTD ⓘ -8.56%
Book/sh ⓘ 16.15P/C ⓘ 13.1EPS past 3/5Y ⓘ -0.15% 3.6%ROE ⓘ 11.93%52W High ⓘ -28.95% ($57.81)Perf Year ⓘ -20.6%
Cash/sh ⓘ 3.14P/FCF ⓘ 20.59Sales past 3/5Y ⓘ -0.81% 2.25%ROIC ⓘ 8.08%52W Low ⓘ 26.28% ($32.53)Perf 3Y ⓘ -12.02%
Dividend Est. ⓘ $0.27 (0.65%)EV/EBITDA ⓘ 13.27EPS Y/Y TTM ⓘ 333.61%Gross Margin ⓘ 61.58%Volatility(W/M) ⓘ 2.25% 2.8%Perf 5Y ⓘ -20.48%
Dividend TTM ⓘ 0.35EV/Sales ⓘ 4.51Sales Y/Y TTM ⓘ 4.79%Oper. Margin ⓘ 24.41%ATR (14) ⓘ 1.09Perf 10Y ⓘ 78.41%
Dividend Ex-Date ⓘ 2026/7/7Quick Ratio ⓘ 2.57EPS Q/Q ⓘ -24.94%Profit Margin ⓘ 19.16%RSI (14) ⓘ 58.49Recom ⓘ 2.23
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.21Sales Q/Q ⓘ 1.83%SMA20 ⓘ 1.45% ($40.49)Beta ⓘ 0.63Target Price ⓘ $43.12
Payout ⓘ 12.88%Debt/Eq ⓘ 0.49Earnings ⓘ 2026/8/5SMA50 ⓘ 8.07% ($38.01)Rel Volume ⓘ 0.61Prev Close ⓘ $41.37
Employees ⓘ 5654LT Debt/Eq ⓘ 0.49EPS/Sales Surpr. ⓘ -0.3% -0.77%SMA200 ⓘ -4.96% ($43.22)Avg Volume(3M) ⓘ 2.71MPrice ⓘ $41.08
IPO ⓘ 1996/6/28Option/Short ⓘ Yes/YesTrades ⓘ 16989Volume ⓘ 1,650,964Change ⓘ -0.7%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Qiagen NV (QGEN) Investment Analysis

What kind of company is Qiagen NV?

키아젠(QGEN) 방어주
Healthcare · Diagnostics & Research
#1050 by Market Cap — Mid-Cap

🧫 This is a global life sciences and diagnostics company that provides molecular diagnostics and sample preparation and analysis technologies. It supplies kits and equipment for extracting and analyzing genetic information from samples, as well as diagnostic tests for tuberculosis and infectious diseases. The company's results are tied to recurring consumables demand and diagnostic and research demand, making it a diagnostics and life sciences play.

Learn more about Qiagen NV →
Market Cap
$8.5B
Approx. KRW 11.6 trillion
⚖️ 3% of Samsung Electronics
Market Cap Rank1050
Employees5,654people
IPO1996/06/28
Current Price$41.08 ≈ 56,280원
NYSE · Netherlands

Key Events

⏰ Upcoming events
🔔 Earnings release D-9
8월 5일 (수) · 장 마감 후
예상 EPS $0.60
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 7월 7일 (화) 주당 $0.35
🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후 EPS -0.3% 매출 -0.8%
🔔 Earnings release 2026년 4월 27일 (월) · 장 마감 후 EPS -0.3% 매출 -1.6%
🔔 Earnings release 2026년 2월 4일 (수) · 장 마감 후 EPS +3.0% 매출 +2.3%
🎯 Ex-div 2026년 1월 8일 (목) 주당 $2.29

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
24.4%
✓ 우수
My positionTop 5%
Low range Average High range
Diagnostics & Research Median -6.9% · Top 4%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
19.2%
✓ 우수
My positionTop 25%
Low range Average High range
Diagnostics & Research Median -3.8% · Top 10%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
61.6%
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 52.1% · Top 32%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
11.9%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -17.0% · Top 23%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
7.1%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -9.3% · Top 19%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
8.1%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 중형주 Median -11.9% · Top 19%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.49
✓ Healthy debt
My positionMid-range
Low range Average High range
Diagnostics & Research Median 0.38
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.21
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 2.23
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.57
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 2.15
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$43.12
현재가 대비 +5.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
15.82배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
2.67
고평가
💡 PEG > 2 — 성장 대비 비싼 편
내년 EPS 예상 성장률
+7.9%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+5.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Generally in line with estimates
0
예상 상회
3
예상 부합
0
예상 하회
0%
상회 비율
-0.0%
평균 서프라이즈
2026.05.06
부합
실적 $0.54 · 예상 $0.54 +0.0%
2026.04.27
부합
-0.3%
2026.02.04
부합
실적 $0.62 · 예상 $0.62 +0.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+1.2%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 5.2% · Bottom 44%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+7.9%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 10.7% · Bottom 34%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+5.9%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 7.2% · Bottom 46%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-0.1%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 4.5% · Bottom 42%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+3.6%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 6.5% · Bottom 45%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+2.3%
부진
My positionBottom 25%
Low range Average High range
방어주 중형주 Median 7.7% · Bottom 11%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+1.8%
평균
My positionMid-range
Low range Average High range
방어주 중형주 Median 4.6% · Bottom 33%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -89%p below the market
QGEN -20.5% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-88.8%p
Significantly behind the market
vs Health Care (XLV)
-45.0%p
Significantly behind the sector average
1-year basis
vs S&P 500
-36.6%p
Significantly behind the market
vs Health Care (XLV)
-40.3%p
Significantly behind the sector average
Current position within 52-week range
Low (-26.3%p) High (-28.9%p)
Current price is 26.3% above the 52-week low and 28.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-36.9%
Annualized volatility
35.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 137-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $41.08 above the midline ($40.49). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD 0.868 · Signal 0.958 · Hist -0.090. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 58.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 53.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
21.22x
✓ Very cheap
My positionTop 5%
Low range Average High range
Diagnostics & Research median 35.22x · Top 1% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
15.82x
✓ Very cheap
My positionTop 25%
Low range Average High range
Diagnostics & Research median 22.77x · Top 12% — relatively cheap within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
2.54x
✓ Cheap
My positionMid-range
Low range Average High range
Diagnostics & Research median 3.37x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
4.03x
✓ Cheap
My positionMid-range
Low range Average High range
Diagnostics & Research median 4.06x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
13.27x
✓ Very cheap
My positionTop 5%
Low range Average High range
Diagnostics & Research median 22.23x · Top 1% — relatively cheap within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
20.59x
✓ Very cheap
My positionTop 25%
Low range Average High range
Diagnostics & Research median 29.34x · Top 17% — relatively cheap within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$43.12 vs. current price +5.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership flow is positive
Institutional net buying +15.5% · Short interest light 3.9% · Short interest up +0.6pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+15.5%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 79.9%
Adequate institutional weight
Healthcare 중형주 Median 89.4%
🧑‍💼 Insiders 0.6%
Low, common among large-caps
Healthcare 중형주 Median 9.4%
👤 Retail investors (estimated) 19.5%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
3.9%
Low — limited short-side pressure
Healthcare 중형주 Median 11.3%
Past 90 days 📈 +0.6%p increase
Short interest days to cover
2.9 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 206.3M주
Float (tradable shares) 204.8M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding QGEN

ETFs with the highest weightings · 10 total shown
GNOM
GNOM
Global X Genomics & Biotechnology ETF
3.63%
$79M
EKG
EKG
First Trust Nasdaq Lux Digital Health Solutions ETF
3.56%
$4M
PBE
PBE
Invesco Biotechnology & Genome ETF
2.03%
$281M
FXH
FXH
First Trust Health Care AlphaDEX Fund
1.50%
$1.0B
GDOC
GDOC
Goldman Sachs Future Health Care Equity ETF
1.39%
$19M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 0.65%
배당보다 주가 성장에 가까운 비중
Dividend Yield
0.65%
Industry average 1.23%
Dividend Per Share
$0.27
Annualized
Payout Ratio
13%
Share of net income paid as dividends
5-Year Growth
-
Annualized dividend growth
📊 총 이력 2002~2025 (5건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.03
2002
$1.15 +3505.8%
2017
$1.36 +17.7%
2024
$0.25 -81.6%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 5건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2025-07-02
$0.250
—
0.51%
2024-01-30
$1.36
—
3.12%
2017-01-25
$1.15
—
4.02%
2002-12-27
$0.030
—
0.58%
2002-12-26
$0.002
—
0.04%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 5,587원
5년 누적 (세후) 2.8만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
QGEN QGEN This Stock
$8.5B21.2 ▲2.5 ▲11.93% ▲0.65% ▼-0.7%
LLY
$1.13T43.1 ▼36.2 ▼107.64% ▲0.58% ▼+0.1%
JNJ
$640.9B30.8 ▼7.5 ▼25.74% ▲2.02% ▲+1.0%
ABBV
$453.9B126.7 ▼- 15221.82% ▲2.67% ▲-0.9%
UNH
$379.3B26.9 ▼3.9 ▼12.49% ▲2.16% ▲-0.7%
MRK
$323.0B36.8 ▼7.0 ▼18.97% ▲2.5% ▲-0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
퀴아젠(QGEN) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
퀴아젠(QGEN)은 분자 진단과 시료 준비·분석 기술을 공급하는 글로벌 생명과학·진단 기업으로, 시료 준비 소모품의 반복 수요와 분자 진단·연구개발 수요에 실적과 주가가 연동되며, 잠복 결핵 등 특화 진단에 강점을 둔 진단·생명과학 종목입니다.
📚 Related Investment Guides
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 키아젠(QGEN)?

키아젠(QGEN) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of QGEN?

The market cap of QGEN is approximately $8.5B, ranking 1,050 within its sector.

Does QGEN pay dividends?

QGEN has a dividend yield of approximately 0.65%, with an annual dividend of $0.27.

What is the P/E ratio of QGEN?

QGEN has a P/E ratio of approximately 21.2x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for QGEN?

QGEN has recorded a 52-week high of $57.81 and a low of $32.53.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.